Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Welcome to Pharm-Olam Insights

Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID-19 and its effect on the clinical landscape.

The Importance of Natural History Study to Rare Disease Drug Development

Rare disease drug development varies from the pathways seen in more established indications. The sample sizes are often...

(4 minute read)

Tags: Rare & Orphan Disease, Pharm-Olam Insights

Pharm-Olam’s Audit-Ready Approach to Database Build

Pharm-Olam is committed to following our industry’s best practices – sometimes even those from other segments of our industry....

(3 minute read)

Tags: Data Management

Current Trends in Systemic Lupus Erythematosus (SLE) Trials

Systemic lupus erythematosus is an autoimmune disease that presents differently in each person. There are roughly 150 people...

(1 minute read)

Tags: Pharm-Olam Insights, Autoimmune

The COVID 19 Map per ClinicalTrial Gov

The COVID Pandemic is continuing to evolve. Governments and companies around the world are striving to develop vaccines and...

(8 minute read)

Tags: Infectious Disease & Vaccines, COVID-19

Pharm-Olam Releases Updated Paper on the Impact of COVID on Clinical Research

Earlier this year, Pharm-Olam partnered with Informa’s Pharma Intelligence to draft a white paper that discusses the...

(1 minute read)

Tags: Infectious Disease & Vaccines, COVID-19, Global Coverage

6 Study Adaptations to Keep Studies Moving Despite COVID-19 Pandemic

The COVID-19 Pandemic continues to evolve and fluctuate across the globe – but not evenly or predictablySome countries have...

(22 minute read)

Tags: Pharm-Olam Insights, Infectious Disease & Vaccines, Investigator Insights,

Managing Patient Enrollment in Acromegaly Rare Disease Studies

In rare disease, every patient matters and it is important for CRO and sponsor medical staff to effectively monitor and...

(2 minute read)

Tags: Rare & Orphan Disease, Pharm-Olam Insights

Brexit is here - Is your clinical trial-ready?

The United Kingdom officially withdrew from the European Union (EU) on Jan 31, 2020. They have until Dec 31, 2020 to complete...

(3 minute read)

Tags: Pharm-Olam Insights, Global Coverage

Join other Clinical Development experts to receive the latest industry news, trends and insights.

Subscribe to our blog and we'll give you our GDPR Controller & Processor Checklist.